

## Aspira Women's Health Enhances its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of OvaWatch

### Description

May 02, 2024 08:00 ET

AUSTIN, Texas, May 02, 2024 (GLOBE NEWSWIRE) — Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the formal launch of an updated OvaWatch ovarian cancer risk assessment test following the completion of all appropriate pre-launch activities.

Adnexal masses develop near the uterus, usually in or around the ovaries, fallopian tubes, and neighboring connective tissues. Most adnexal masses do not pose a serious threat to the health of a woman and resolve on their own within a few months. Others will require treatment or surgery. OvaWatch utilizes an AI-powered algorithm to assess malignancy risk of adnexal masses when initial clinical assessment indicates the mass is indeterminant or benign. With a negative predictive value of 99%, OvaWatch can help physicians confidently determine the appropriate care plan over time.

"We are proud to be able to meaningfully enhance the OvaWatch offering with the longitudinal monitoring feature," said Dr. Sandra Milligan, President of Aspira Women's Health. "More than 1.2 million women will present with an adnexal mass each year, and OvaWatch offers doctors and their patients a powerful tool to assess malignancy risk when it is identified and over time. We believe OvaWatch will help improve care decisions for women with adnexal masses, especially when surgery may be unnecessary or premature."

### About Aspira Women's Health Inc.

Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.

OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuite<sup>SM</sup>. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women planned for surgery.

Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDx<sup>SM</sup> risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our

current tests. In endometriosis, EndoCheck<sup>SM</sup> is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDx<sup>SM</sup> test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.

### **Forward-Looking Statements**

This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the pipeline development and other statements that are predictive in nature. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “designed to,” “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release and other factors that may cause such differences include the satisfaction of customary closing conditions related to the offering and the expected timing of the closing of the offering. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira’s expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company’s assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

### ***Investor Relations Contact:***

Torsten Hombeck, Ph.D.  
Chief Financial Officer  
[Aspira Women’s Health](#)  
[Investors@aspirawh.com](mailto:Investors@aspirawh.com)